Takeda Pharmaceutical Company Profile (OTCMKTS:TKPYY)

Analyst Ratings

Consensus Ratings for Takeda Pharmaceutical (OTCMKTS:TKPYY) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Takeda Pharmaceutical (OTCMKTS:TKPYY)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Takeda Pharmaceutical (OTCMKTS:TKPYY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/1/2014$0.21ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/5/2014Q4$0.29ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Takeda Pharmaceutical (OTCMKTS:TKPYY)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Takeda Pharmaceutical (OTCMKTS:TKPYY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Takeda Pharmaceutical (OTCMKTS:TKPYY)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Takeda Pharmaceutical (OTCMKTS:TKPYY)
DateHeadline
07/26/16 08:29 AMTakeda Pharmaceutical Co., Ltd. :TKPYY-US: Earnings Analysis: 2016 By the Numbers : July 26, 2016 -
07/21/16 06:49 AMTakeda Said to Explore Sale of Chemicals Unit to Raise Cash -
07/21/16 03:35 AMStock Picker Wahei Takeda, Dubbed Japan’s Buffett, Dies at 83 -
07/15/16 12:00 PMTakeda Aims To Raise $500,000 for Team Challenge for Crohn's & Colitis - [PR Newswire] - DEERFIELD, Ill., July 15, 2016 /PRNewswire/ -- Some will be walking and others will be running but all will have smiles on their faces as more than 100 employees of Takeda Pharmaceuticals cross the finish line of the Napa-to-Sonoma Wine Country Half Marathon on July 17 to help raise awareness and understanding of inflammatory bowel diseases, conditions that affect more than 1.6 million people in the U.S. Takeda employees are participating in the half marathon as part of the Crohn's & Colitis Foundation of America's (CCFA) Team Challenge endurance training and fundraising program. CCFA is one of the national charity partners for the Napa-to-Sonoma Wine Country Half Marathon.
07/13/16 07:00 AMTakeda and the Crohn's & Colitis Foundation of America Partner to Introduce 'IBD Unmasked' A First-of-its-Kind Awareness Campaign - [PR Newswire] - In February 2016, Takeda Pharmaceuticals U.S.A., Inc. ("Takeda") invited seven individuals from around the country to meet with Marvel Custom Solutions in New York City and share their stories of living with Crohn's disease (CD) or ulcerative colitis (UC) – the two most common types of IBD. During a day-long workshop, the brave group opened up about having IBD and the emotional and physical impact on their lives, sharing their candid experiences with Marvel Custom writers.
07/13/16 03:55 AMIBD Unmasked, a First-of-its-Kind Global Awareness Initiative, Launches to Support and Empower the Inflammatory Bowel Disease Community - [PR Newswire] - If someone with inflammatory bowel disease (IBD) was a Super Hero, what would that hero look like? Perhaps bravery, strength, determination - three characteristics demonstrated by the IBD community members who battle this disease every day. Today, Takeda Pharmaceutical Company Limited [TSE: 4502], launched IBD Unmasked, a first-of-its-kind global initiative designed to raise awareness of the unsung Super Heroes of the global IBD community, and celebrated through a unique collaboration with the creative geniuses at Marvel Custom Solutions.
07/06/16 08:32 AMTakeda nabs ex-U.S. rights to investigational stem cell treatment for Crohn's-related fistulas
07/06/16 07:00 AMTakeda Receives European Commission Approval of ADCETRIS® (brentuximab vedotin) for Consolidation Treatment in Post-Transplant Hodgkin Lymphoma - [Business Wire] - CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESSWIRE)-- Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Commission (EC) has extended the current conditional marketing authorization ...
07/05/16 07:00 AMTakeda Submits a New Drug Application for Novel, Oral Proteasome Inhibitor Ixazomib in Japan - [Business Wire] - OSAKA, Japan--(BUSINESSWIRE)-- Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that it has submitted a New Drug Application (“NDA”) to the Ministry of Health, Labour and Welfare in Japan for ixazomib, the first oral proteasome inhibitor for the treatment of relapsed or refractory multiple myeloma. The trial demonstrated that the all-oral triplet regimen containing ixazomib, lenalidomide and dexamethasone significantly extended the progression-free survival (PFS) in patients with relapsed or refractory multiple myeloma, with a manageable safety profile and the convenience and practicality of oral dosing. “Multiple myeloma remains a devastating, relapsing and incurable rare cancer.
07/01/16 09:26 AMReport Published: “Epithelial Ovarian Cancer – Pipeline Review, H1 2016”
07/01/16 07:00 AMTakeda to Partner with Altos Therapeutics to Develop Promising Compound for the Treatment of Gastroparesis - [Business Wire] - OSAKA, Japan & LOS ALTOS, Calif.--(BUSINESSWIRE)-- Takeda Pharmaceutical Company Limited (TSE: 4502) and Altos Therapeutics LLC today jointly announced the companies have entered into a definitive agreement to further the development of Altos’s proprietary compound ATC-1906. Additionally, the agreement includes an exclusive option for Takeda to acquire Altos beginning on the date of the agreement and continuing for a period of time following the completion of ongoing Phase 1 studies of ATC-1906. The parties envision future development of ATC-1906 for the treatment of gastroparesis (GP) and its symptoms.
06/25/16 10:27 AMTakeda’s norovirus vaccine first to reach human trials
06/21/16 08:00 PMTB Alliance and Takeda Announce Advancement of Joint Program Investigating Promising Compounds for Novel TB Therapies Through Global Health Innovative Technology Fund - [Business Wire] - The joint research program is funded through the Global Health Innovative Technology (GHIT) Fund, established for the purpose of promoting research and development of pharmaceutical products, vaccines and diagnostics needed for communicable diseases. In June 2013, TB Alliance and Takeda initiated a program to screen Takeda’s library of 20,000 proprietary compounds to identify potential candidates that showed promise to be further developed into new TB treatments. For Takeda, this program with TB Alliance is an excellent opportunity to leverage, as part of Takeda’s corporate social responsibility program, the company’s drug discovery expertise for communicable diseases, in addition to Takeda’s focus on the oncology, gastroenterology and central nervous system therapeutic areas.
06/16/16 07:00 PMTri-Institutional Therapeutics Discovery Institute expands focus to include antibody drug discovery research
06/16/16 07:00 PMTakeda Pharmaceutical : Tri-Institutional Therapeutics Discovery Institute, Inc. Expands Partnership with Takeda Pharmaceutical Company, Ltd.
06/16/16 05:00 PMTri-Institutional Therapeutics Discovery Institute, Inc. Expands Partnership with Takeda Pharmaceutical Company, Ltd. - [Business Wire] - NEW YORK & OSAKA, Japan--(BUSINESSWIRE)-- Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine today announced that they will expand the focus of the successful Tri-Institutional Therapeutics Discovery Institute, Inc. (Tri-I TDI), a partnership established in 2013 to expedite early-stage drug discovery of innovative new therapies. Under this expansion, Tri-I TDI will extend its current relationship with its industry partner, Takeda Pharmaceutical Company, Ltd. (TSE:4502) from the realm of small molecule discovery into the new research area of antibody drug discovery. All three institutions will benefit from Tri-I TDI’s expansion.
06/16/16 11:17 AMResearch report covers the Blood Cancer Treatment Market Growth, 2016-2026
06/16/16 10:45 AMMersana to advance cancer killing drug to clinical trials with $33M investment -
06/16/16 06:30 AM[$$] Mersana Therapeutics Raises $33M Series C, Plans Cancer Clinical Trials -
06/15/16 06:41 PMCelgene joins DNDi's 'Drug Discovery Booster'
06/11/16 12:31 PMEXAMINE Trial Post-Hoc Analyses of Mortality Data Regarding Cardiovascular Safety of Alogliptin Presented at American Diabetes Association's 76th Scientific Sessions and Published in Diabetes Care - [PR Newswire] - This data was presented at the American Diabetes Association's 76th Scientific Sessions, and also published in Diabetes Care. "Heart disease, or CV disease, is the leading cause of death in patients with Type 2 diabetes,2 and is responsible for between 50 and 80 percent of deaths in people with diabetes,3 so it's critical we have a clear understanding of the impact these medications have on patients with Type 2 diabetes who are at a high risk for CV diseases such as those involved in EXAMINE," said William B. White, MD, Professor, Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, Connecticut, U.S., on behalf of the EXAMINE Steering Committee and Investigators.
06/06/16 08:38 AMTakeda to Present New Data at the American Diabetes Association's 76th Scientific Sessions - [PR Newswire] - OSAKA, Japan, June 6, 2016 /PRNewswire/ -- Takeda Pharmaceuticals Company Limited , ("Takeda") will present eight abstracts at the American Diabetes Association's 76 th Scientific ...
06/03/16 09:50 AMHusband blames pharmaceutical companies for wife's death
06/01/16 09:00 AMTrintellix (vortioxetine) Now Available in U.S. Pharmacies - [PR Newswire] - DEERFIELD, Ill. and OSAKA, Japan, June 1, 2016 /PRNewswire/ -- Takeda Pharmaceuticals U.S.A., Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), and Lundbeck announced today that Trintellix (vortioxetine), a once-daily oral antidepressant indicated for the treatment of major depressive disorder (MDD) in adults, is now available in United States pharmacies. Takeda and Lundbeck recently announced that the trade name for the vortioxetine product in the United States would be changed to Trintellix to avoid name confusion. The formulation, indication and dosages of Trintellix remain the same as that of Brintellix, which was originally approved by the U.S. Food and Drug Administration (FDA) in September 2013.
05/26/16 07:56 PMValeant rejected joint takeover bid from Takeda, TPG in spring: WSJ - (Reuters) - Valeant Pharmaceuticals International Inc received a joint takeover offer from Japan's Takeda Pharmaceutical Co Ltd and TPG Capital Management LP [TPG.UL] this spring that the Canadian...
03/15/16 07:58 AMUPDATE 1-Orexigen buys U.S. obesity pill rights from Takeda, partners Valeant - March 15 (Reuters) - Orexigen Therapeutics Inc said it agreed to buy the U.S. rights to its flagship obesity drug from partner Takeda Pharmaceutical Co Ltd and will tap Canada's Valeant...
02/09/16 12:10 PMTakeda Pharmaceutical Co., Ltd. Earnings Analysis: Q3, 2016 By the Numbers -
02/08/16 03:10 PMMersana plans human trials of first cancer drug by this summer -
02/03/16 07:35 PMFDA Psychopharmacologic Drug Advisory Committee Supports the Effectiveness of Brintellix® (vortioxetine) in Treating Certain Aspects of Cognitive Dysfunction in Major Depressive Disorder (MDD) - [PR Newswire] - OSAKA, Japan and VALBY, Denmark, Feb. 3, 2016 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) today announced that the U.S. Food and Drug Administration's (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) voted 8 to 2 that the companies presented substantial evidence to support the effectiveness of Brintellix (vortioxetine) for treating certain aspects of cognitive dysfunction in adults with Major Depressive Disorder (MDD). Earlier today, the committee also discussed that cognitive dysfunction in MDD represents an appropriate drug development target.
02/03/16 02:07 PMTakeda Pharmaceutical Co., Ltd. – Value Analysis (US OTC:TKPYY) : February 3, 2016 -
02/02/16 10:38 PMTakeda Assembles Team to Evaluate Zika Vaccine Possibilities -
01/27/16 11:01 AM12:01 pm Takeda Pharma confirms FDA approval of Dexilant SoluTab delayed-release orally disintegrating tablets -
01/27/16 10:59 AMFDA Approves Takeda's Dexilant SoluTab (dexlansoprazole) - [PR Newswire] - DEERFIELD, Ill., Jan. 27, 2016 /PRNewswire/ -- Takeda Pharmaceuticals U.S.A., Inc., (Takeda) (TSE: 4502) today announced that the United States (U.S.) Food and Drug Administration (FDA) approved Dexilant SoluTab delayed-release orally disintegrating tablets, a new formulation of dexlansoprazole that can be taken by allowing the tablet to melt in the patient's mouth. Dexilant SoluTab is a proton pump inhibitor (PPI) indicated for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) and the maintenance of healed erosive esophagitis (EE) and relief of heartburn in adults 18 years and older.
01/25/16 10:45 AMGlaxo evaluating possibility of using vaccine technology for Zika - [Reuters] - GlaxoSmithKline Plc is concluding feasibility studies evaluating whether its vaccine technology is suitable for the Zika virus, which has been linked to brain damage in thousands of babies in Brazil, a spokeswoman told Reuters. Zika will likely spread to all countries in the Americas except for Canada and Chile, the World Health Organization said on Monday.
01/13/16 03:00 PMAsia's Biggest Drugmaker Eyes Greener Shores as Fortunes Fade at Home -
01/12/16 07:47 AMThis 230-year-old Japanese drugmaker wants to turn into 'a 33,000-person startup' -
01/05/16 05:00 PMTakeda Acquires U.S. Biologics Manufacturing Facility - [Business Wire] - OSAKA, Japan--(BUSINESSWIRE)-- Takeda Pharmaceutical Company Limited (TOKYO:4502) (“Takeda”) today announced the acquisition of a biologics manufacturing facility located in Brooklyn Park, Minnesota, U.S., ...
12/28/15 03:45 PMTakeda, Teva Reveal Outlook of Japanese Business Venture -
12/28/15 08:55 AMTeva Pharmaceutical: Joint Venture With Takeda Will Be 'Instantly Accretive' To 2016 EPS And Beyond -
12/27/15 08:55 PMCORRECTING and REPLACING Takeda Provides Further Information about Its New Business Venture with Teva - [Business Wire] - OSAKA, Japan & JERUSALEM--(BUSINESSWIRE)-- Insert after fifth paragraph, first sentence of release: The new business venture will be instantly accretive to Teva's non GAAP EPS in 2016 and beyond. Takeda Pharmaceutical Company Limited (TOKYO:4502) and Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - News) (TASE:TEVA.TA - News) today made the below follow-up announcement regarding the overview of their new business venture in Japan, which was initially disclosed on November 30, 2015 in the press release titled, "Teva and Takeda establish unique partnership to meet the wide-ranging needs of patients and growing importance of generic medicines use in Japan". The new business venture, to be established in or after April 2016, will deliver Teva's high-quality generic medicines and some of Takeda's long listed products to patients and healthcare professionals in Japan, leveraging Takeda's corporate brand and unique distribution network in Japan and Teva's wide product portfolio and cutting-edge business efficiency.
12/27/15 07:44 PMINSERTING and REPLACING Takeda Provides Further Information about its New Business Venture with Teva - [Business Wire] - OSAKA, Japan & Jerusalem--(BUSINESSWIRE)-- Insert after 1st sentence in last bullet of release: The new business venture will be instantly accretive to Teva's non GAAP EPS in 2016 and beyond. The corrected ...
12/16/15 04:39 AMAstraZeneca to buy Takeda's lung business for £383m -

Social

About Takeda Pharmaceutical

Takeda Pharmaceutical logoTakeda Pharmaceutical Company Limited is a Japan-based company engaged in the pharmaceutical business. The Ethical Pharmaceutical segment is engaged in the manufacture and sale of pharmaceutical products, such as therapeutic substances for diabetes, circulatory drugs, anticancer drugs, drugs for central neurological diseases, digestive system drugs, hormonal agents, osteoporosis drugs, antibiotic agents, allergy medications, vitamin drops and vaccines, among others. The Healthcare segment manufactures and sells general drugs and medicines, as well as quasi drugs. The Others segment is involved in the manufacture and sale of reagents, clinical diagnostics and chemical products. As of March 31, 2014, the Company had 146 subsidiaries and 17 associated companies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: OTCMKTS
  • Symbol: TKPYY
  • CUSIP:
Key Metrics:
  • Previous Close: $21.60
  • 50 Day Moving Average: $21.22
  • 200 Day Moving Average: $22.96
  • P/E Ratio: 44.95
  • P/E Growth: 0.00
  • Market Cap: $33.85B
  • Beta: 0.24
  • Current Year EPS Consensus Estimate: $N/A EPS
  • Next Year EPS Consensus Estimate: $N/A EPS
Additional Links:
Takeda Pharmaceutical (OTCMKTS:TKPYY) Chart for Wednesday, July, 27, 2016